Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings Inc (NYSE American: SENS) is a pioneer in long-term implantable continuous glucose monitoring systems, transforming diabetes care through innovative medical technology. This news hub provides investors and healthcare professionals with timely updates on corporate developments, regulatory milestones, and clinical advancements.
Access official press releases covering financial results, product approvals, and strategic partnerships alongside analysis of key operational updates. Our curated news collection includes updates on Eversense CGM system enhancements, international market expansions, and clinical study outcomes.
Stay informed about critical developments including FDA submissions, European regulatory updates, and partnership announcements with global healthcare distributors. Bookmark this page for direct access to primary source materials essential for tracking Senseonics' progress in medical device innovation.
Senseonics Holdings, Inc. (NYSE American: SENS) and Mercy healthcare system have announced the first commercial use of Eversense 365, the world's only 365-day continuous glucose monitoring (CGM) system. This milestone marks the beginning of the commercial launch by Ascensia Diabetes Care for the FDA-approved Eversense 365, which offers patients with Type 1 and Type 2 diabetes a full year of accurate glucose monitoring with minimal interruptions.
Key features of Eversense 365 include:
- One-year monitoring duration
- No additional sensor replacements required
- Only one calibration per week
- Improved glycemic control and reduced diabetes management distress
- Potential to lower overall healthcare costs
Mercy, serving 3 million patients annually, estimates that approximately 30,000 of its patients could benefit from this CGM system. The collaboration between Senseonics and Mercy aims to make this technology accessible to more patients across the U.S.
Ascensia Diabetes Care has launched the Eversense 365 continuous glucose monitoring (CGM) system in the US. Developed by Senseonics Holdings (NYSE American: SENS), it's the world's first and only One Year CGM system, recently cleared by the FDA for people with type 1 and type 2 diabetes aged 18 and older.
Key features of Eversense 365 include:
- One-year accurate monitoring with minimal disruptions
- A tiny sensor that rests under the skin
- Exceptional accuracy over one year
- Reduced diabetes distress and improved glucose control
- Broad commercial insurance coverage
Eligible individuals can pay as little as $199 out of pocket for one year of continuous glucose monitoring through the new Eversense 365 Payment Assistance and Simple Savings (PASS) program.
Senseonics Holdings, Inc. (NYSE American: SENS) and Ascensia Diabetes Care announced FDA clearance for the Eversense 365 CGM system, the world's first one-year continuous glucose monitoring system for people with Type 1 and Type 2 diabetes aged 18 and older. This breakthrough device offers:
- 365-day sensor longevity, reducing frequent sensor changes
- High accuracy and dependability over 12 months
- Removable transmitter for flexibility
- On-body vibration alerts for discretion
Eversense 365 is cleared as an integrated CGM (iCGM) system, compatible with insulin pumps for automated insulin delivery. The U.S. launch is expected in Q4 2024, with Ascensia working to ensure immediate access for users.
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place in New York, NY on September 10, 2024.
Key points:
- Management will present at 11:30 am ET
- One-on-one meetings will be held
- A live and recorded webcast will be available on the company's website
This conference provides Senseonics an opportunity to showcase its innovative CGM technology and engage with potential investors, potentially impacting the SENS stock.
Senseonics Holdings, Inc. (NYSE American: SENS) reported financial results for Q2 2024. Key highlights:
- Revenue of $4.9 million, up 18% year-over-year
- U.S. revenue increased to $3.0 million from $1.8 million in Q2 2023
- Net loss of $20.3 million, or $0.03 per share
- Cash, cash equivalents, restricted cash, and short-term investments totaled $84.9 million
The company is preparing for the Q4 2024 launch of its 365-day Eversense® CGM system, pending FDA clearance. Senseonics maintains its 2024 global net revenue outlook of $22-24 million, expecting to double U.S. new patient starts and increase the global installed base by approximately 50% compared to 2023.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for diabetes patients, has announced its schedule for the second quarter 2024 earnings release and conference call. The financial results will be released after market close on Thursday, August 8, 2024. A conference call to review the Q2 2024 performance will be held at 4:30 p.m. Eastern Time on the same day.
The call will be simultaneously webcast and accessible via the company's website. Investors can join the conference call by dialing 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International) with passcode 4740206.
Senseonics Holdings, a medical tech company specializing in long-term, implantable continuous glucose monitoring (CGM) systems, has released its business updates and financial outlook for 2024. The first half of 2024 saw a 21% increase in net revenue to $10 million and over a 200% rise in new patient starts in the U.S. compared to the same period in 2023. The FDA review of the new 365-day Eversense system is on track for a Q4 2024 launch. Collaborations with Mercy Health are progressing with provider training and patient identification underway.
For the full year 2024, Senseonics expects global net revenue between $22 million and $24 million, with significant growth in U.S. patient starts and a 50% increase in the global installed base. However, inventory dynamics may affect Q3 sales, with an anticipated acceleration in Q4. Cash utilization is projected to remain stable at around $70 million.
Senseonics Holdings, a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced a business update and analyst event. This will take place during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL. The event is scheduled for Sunday, June 23, 2024, with breakfast and refreshments starting at 9:15 am ET, followed by a management presentation at 10:00 am ET. Attendees can access the presentation via live and recorded webcast on the company's website. In-person attendance requires advanced registration by June 21, 2024, through emailing Hannah Jeffrey at hannah@gilmartinir.com.
Senseonics Holdings, a medical technology firm specializing in long-term, implantable continuous glucose monitoring (CGM) systems, announces its participation in the Sidoti Small Cap Conference. The event will take place virtually on June 12, 2024, at 1:45 pm ET. Management will hold one-on-one meetings and present key insights. The live and recorded webcast of the presentation will be available on the company's Investor Relations section at www.senseonics.com.
Senseonics Holdings, a medical technology firm specializing in long-term, implantable continuous glucose monitoring (CGM) systems, reported its Q1 2024 financial results.
The company achieved $5.1 million in revenue, a 22% increase compared to Q1 2023. However, gross profit declined to $0.3 million due to higher fixed manufacturing costs.
Notable achievements include the integration of Eversense CGM with Mercy health system, the FDA iCGM designation for Eversense, and the filing for the next-generation 365-day system.
Despite these advancements, the firm posted a net loss of $18.9 million, or $0.03 per share, significantly down from a $1.3 million net income in Q1 2023. First half 2024 revenue is projected at $10 million, a 16% growth year-over-year.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
